Business news

    Invex Therapeutics (ASX:IXC) receives German approval for brain pressure drug clinical trial

    Article Image

    Invex Therapeutics (ASX:ISC) has received regulatory approval in Germany to commence the IIH EVOLVE Phase III clinical trial for patients with Idiopathic Intracranial Hypertension (IIH).

    Invex says it's the first national regulatory clearance in Europe, and is a key step towards obtaining market approval of its drug, Presendin™, in the European Union, United Kingdom, and Australia.

    IIH EVOLVE is a randomised, placebo-controlled, double-blind trial that will randomise 240 patients to receive either Presendin™ or placebo, administered once weekly over 24 weeks.

    The primary endpoint is the change in intracranial pressure from baseline, with key secondary endpoints related to vision and headache outcome measures.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa